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subsequent incidence of colorectal cancer: 
results from the 45 and Up Study
Abstract 
Objective: To investigate the association of colorectal cancer (CRC) screening 
history and subsequent incidence of CRC in New South Wales, Australia. 
Design, setting and participants: A total of 196 464 people from NSW recruited 
to the 45 and Up Study, a large Australian population-based prospective study, by 
completing a baseline questionnaire distributed from January 2006 to December 
2008. Individuals without pre-existing cancer were followed for a mean of 3.78 
years (SD, 0.92 years) through linkage to population health datasets.
Main outcome measures: Incidence of CRC; hazard ratio (HR) according to 
screening history, adjusted for age, sex, body mass index, income, education, 
remoteness, family history, aspirin use, smoking, diabetes, alcohol use, physical 
activity and dietary factors.
Results: Overall, 1096 cases of incident CRC accrued (454 proximal colon, 240 
distal colon, 349 rectal and 53 unspecified cancers). Ever having undergone 
CRC screening before baseline was associated with a 44% reduced risk of 
developing CRC during follow-up (HR, 0.56; 95% CI, 0.49–0.63) compared 
with never having undergone screening. This effect was more pronounced for 
those reporting endoscopy (HR, 0.50; 95% CI, 0.43–0.58) than those reporting 
faecal occult blood testing (FOBT) (HR, 0.61; 95% CI, 0.52–0.72). Associations 
for all screening exposures were strongest for rectal cancer (HR, 0.35; 95% CI, 
0.27–0.45) followed by distal colon cancer (HR, 0.60; 95% CI, 0.46–0.78), while 
relationships were weaker for cancers of the proximal colon (HR, 0.76; 95% CI, 
0.62–0.92).
Conclusion: CRC incidence is lower among individuals with a history of CRC 
screening, through either FOBT or endoscopy, compared with individuals who 
have never had CRC screening, lasting for at least 4 years after screening.
W
ith a mean of 43.8 new cas-
es diagnosed per 100 000 
individuals in 2008, 
Australia has one of the highest age-
standardised colorectal cancer (CRC) 
incidence rates worldwide, account-
ing for 12.7% of total cancers and 10% 
of all cancer deaths nationally.1
Survival from CRC highly depends 
on stage at diagnosis, and clinical tri-
als have demonstrated that screen-
ing using faecal occult blood testing 
(FOBT) increases the detection rate of 
early-stage disease and reduces CRC 
mortality.2 Further, the efficacy of en-
doscopic polypectomy in preventing 
adenomas from progressing to CRC 
has led to a decrease in the incidence 
of CRC in screening trials.3 As a re-
sult, population-based screening 
programs to reduce mortality from 
CRC have been implemented in many 
nations in recent years.4-6
In Australia, national guidelines 
for CRC screening were introduced in 
1999, recommending asymptomatic 
persons aged 50 years and over be 
screened using FOBT at least every 
2 years.7 However, CRC screening 
tests were not freely available until 
the National Bowel Cancer Screening 
Program (NBCSP) was launched 
in 2006 with a one-off faecal oc-
cult blood test mailed to all people 
turning 55 and 65, and, from 2008, 
additionally to people turning 50.4 
Although NBCSP-detected cancers 
are being diagnosed at an earlier 
stage than symptomatic cancers,8,9 
the effects of opportunistic screening 
that occurred before the NBCSP on 
CRC incidence remain largely unex-
plored. Observational data on CRC 
incidence after CRC screening do not 
directly indicate screening effective-
ness in reducing incidence, as cancers 
diagnosed after screening constitute 
those either missed at screening or 
arising de novo during the interval 
between screens (interval cancer), 
and a reduced incidence compared 
with non-screened individuals is to 
be expected. However, such data are 
useful in providing a real-world in-
dication of the likely outcomes and 
health services use after CRC screen-
ing in the general population and giv-
ing indirect insights into the impact 
of screening.10,11
In this study, we present data on 
the relationship between reported 
CRC screening history and CRC in-
cidence in a large population-based 
Australian cohort study, the 45 and 
Up Study.
Methods
Study population
The 45 and Up Study is a popula-
tion-based Australian cohort study 
designed to investigate healthy age-
ing.12 Briefly, eligible participants 
were randomly selected from the 
Australian universal health insur-
ance records (Medicare Australia). 
A total of 267 113 individuals (123 906 
men and 143 207 women) aged  45 
years from the general population in 
New South Wales joined the study by 
completing a postal questionnaire 
(distributed from January 2006 to 
December 2008) and giving written 
consent. Ethics approval for the study 
was provided by the University of 
New South Wales Human Research 
Ethics Committee and the NSW 
Population and Health Services 
Research Ethics Committee.
We excluded participants with pre-
existing cancer (other than non-mel-
anoma skin cancer), missing date of 
study entry, body mass index (BMI) 
outside the range of 15–50 kg/m2, 
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and with invalid or most likely im-
plausible values for physical activ-
ity and diet as previously defined.13 
We excluded 55 777 participants 
with pre-existing cancer (other than 
non-melanoma skin cancer), 11 with 
missing date of study entry, 2113 with 
BMI outside the range of 15–50 kg/m2 
and 12 759 with invalid or most likely 
implausible values for physical activ-
ity and diet. Exclusions left 196 464 
participants for analysis.
Exposure assessment and 
definitions of variables
Information on all variables was 
derived from the self-administered 
questionnaire.14 The questionnaire 
included information on sociodemo-
graphic characteristics, medical 
history, body weight and height, 
smoking, alcohol, diet and physical 
activity. 
For screening history, partici-
pants were asked whether they had 
ever been screened for CRC, and if 
so which test they had undergone 
(FOBT, sigmoidoscopy or colono-
scopy). Year of most recent test was 
also recorded. The following ex-
posure groups were defined: ever 
versus never screened, time since 
last screening (never, screened  3 
years ago, screened > 3 years ago), 
screening modality (ever FOBT v nev-
er screened; ever endoscopy v never 
screened) and time since last screen-
ing according to single screening 
procedures. Initially, no distinction 
was made between primary screen-
ing by endoscopy or endoscopy after 
another screening procedure, most 
likely FOBT. However, we separately 
evaluated primary screening by en-
doscopy in additional analyses. 
Ascertainment of colorectal cancer
Information on cancer incidence was 
obtained through record linkage with 
the NSW Central Cancer Registry. 
For our analysis, the specific censor-
ing date at which the cancer regis-
try was considered complete was 31 
December 2008. Registry information 
was complemented with record data 
from the NSW Admitted Patient Data 
Collection (APDC) for the period 
from 1 January 2009 to 31 December 
2011. The APDC is a complete census 
of all hospital admissions and dis-
charges in NSW and contains, among 
other details, the principal reason for 
admission. As the primary treatment 
of CRC is surgical, the APDC is con-
sidered to provide reliable independ-
ent data on such diagnoses. Recent 
studies on CRC and breast cancer 
have shown that cancer diagnosis 
can be accurately identified using 
hospital data.15,16 
We only considered first prim-
ary incident cases of CRC and par-
ticipants were followed up from 
study entry to cancer diagnosis, 
death or follow-up termination (31 
December 2011), whichever came 
first. Incidence data were coded us-
ing the International Classification 
of Diseases for Oncology, 3rd edition 
(ICD-O-3), with CRC comprising 
C18–C20 (excluding C18.1, cancers 
of the appendix). Proximal colon 
tumours included the caecum, as-
cending colon, hepatic flexure, and 
transverse colon (C18.0, 18.2–18.4). 
Distal colon tumours included the 
splenic flexure (C18.5), and descend-
ing (C18.6) and sigmoid (C18.7) colon. 
Overlapping lesions (C18.8) and un-
specified colon (C18.9) were grouped 
among all colon cancers only (C18.0, 
C18.2–C18.9). Cancer of the rectum 
included tumours occurring at the 
rectosigmoid junction (C19) and rec-
tum (C20). Anal canal tumours were 
excluded.
Statistical analysis
Associations between history of CRC 
screening and incidence of CRC were 
investigated by calculating hazard ra-
tios (HRs) using proportional hazards 
regression stratified by age. Age was 
taken as the underlying time metric, 
with entry and exit time defined as 
the participant’s age at recruitment 
and age at cancer dia gnosis or censor-
ing, respectively. HRs are presented 
in relation to never screened individ-
uals and are adjusted for sex; BMI 
(per kg/m2); highest qualification (no 
school, intermediate/high school, ap-
prenticeship, university), household 
income (< $20 000, $20 000–$49 999, 
$50 000–$69 999, and  $70 000); re-
moteness based on the Accessibility/
Remoteness Index of Australia (city, 
regional, remote); a diagnosis of dia-
betes; family history of CRC; aspirin 
use; smoking (never, former, current); 
alcohol use (drinks/day); vigorous 
physical activity (none, 0 to 1 hour/
week, > 1 to 3.5 hours/week, > 3.5 
hours/week); and intake of red meat, 
processed meat, cereals, fruits, veg-
etables and wholemeal bread.
To appropriately handle missing 
data (up to 13% missing data for 
some variables), we used multiple 
1  General characteristics of the 196 464 included participants from the 45 and Up Study, by screening 
history
Never screened 
(n = 103 977)
Ever screened 
(n = 92 487) P for comparison
Age, mean (SD) 59.7 (11.1) 62.8 (10.1) < 0.001
Body mass index, mean (SD) 27.0 (5.0) 26.9 (4.8) < 0.001
Men 41.1% 44.6% < 0.001
Diabetes 8.0% 8.1% 0.95
University education 23.8% 25.3% < 0.001
Yearly household income  $70 000 27.1% 26.8% 0.06
Remote 2.3% 1.8% < 0.001
First-degree relative with CRC 7.2% 20.0% < 0.001
Regular aspirin use 17.1% 22.5% < 0.001
Former smokers 32.7% 36.0% < 0.001
Current smokers 9.7% 5.4% < 0.001
Alcoholic drinks per day* 1.47 1.50 < 0.001
Vigorous activity > 3.5 hours/week 8.8% 8.6% 0.18
Red meat  5 times/week 20.9% 22.4% < 0.001
Processed meat  5 times/week 5.4% 5.0% < 0.001
Fruits  2 serves/day 55.9% 60.7% < 0.001
Vegetables  5 serves/day 32.8% 36.0% < 0.001
Breakfast cereals > 1 times/week 76.5% 82.9% < 0.001
Wholegrain bread  5 serves/week 47.1% 51.6% < 0.001
CRC = colorectal cancer. * Among drinkers only. 
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imputation techniques (PROC MI and 
PROC MIANALYZE in SAS).17 All 
variables included in the multivariate 
model were included in the imputa-
tion procedure, and five imputation 
cycles were performed.
In sensitivity analyses, we exclud-
ed cases occurring during the first 
2 years of follow-up and restricted 
the analysis to individuals with com-
plete information on all variables to 
compare results with those obtained 
using multiple imputation.
All analyses were performed using 
SAS, version 9.3 (SAS Institute) and 
two-sided P values were considered.
Results
During a mean follow-up of 3.78 
years (SD, 0.92 years) — 741 829 per-
son-years — a total of 1096 cases of 
incident CRC accrued (454 proximal 
colon, 240 distal colon, 349 rectal and 
53 unspecified cancers). 
Screened individuals were more 
likely to have a family history of CRC 
and less likely to be current smokers 
than unscreened individuals (Box 1).
Having ever been screened before 
baseline was associated with a 44% 
reduced risk of developing CRC 
during follow-up in comparison to 
never having been screened (HR, 
0.56; 95% CI, 0.49–0.63) (Box 2). HRs 
of CRC were 0.61 (95% CI, 0.52–0.72) 
and 0.50 (95% CI, 0.43–0.58), respec-
tively, among those reporting ever 
having had FOBT and those report-
ing endoscopy versus no screening. 
We observed negligible differences 
in the HRs for those screened more 
than 3 years versus 3 years or less 
before baseline. 
In relation to CRC subtypes, the in-
verse association between all screen-
ing exposure variables was strongest 
for rectal (HR, 0.35; 95% CI, 0.27–0.45) 
followed by distal cancer (HR, 0.60; 
95% CI, 0.46–0.78), while the relation-
ship was weaker for proximal colon 
cancers (HR, 0.76; 95% CI, 0.62–0.92) 
(Box 3). 
Similar HRs were observed in sub-
group analyses; for example, men and 
women and across smoking status 
(data not shown). The risk of devel-
oping CRC was particularly low for 
individuals with a family history of 
CRC (HR, 0.38; 95% CI, 0.27–0.54) 
compared with individuals without 
(HR, 0.59; 95% CI, 0.52–0.68) (P for 
interaction, 0.02). 
Restricting the analysis to indi-
viduals with complete information 
on all variables (626 CRC cases) did 
not materially alter the results (data 
not shown). Exclusion of patients 
diagnosed during the first 2 years of 
follow-up slightly attenuated results 
for FOBT (HR, 0.72; 95% CI, 0.58–0.90), 
while estimates remained virtually 
unchanged for ever having had an en-
doscopy (HR, 0.52; 95% CI, 0.42–0.65). 
Discussion
In this large population-based pro-
spective study, a history of CRC 
screening was related to a 44% lower 
risk of subsequent CRC compared 
with never having undergone screen-
ing. Reductions in CRC risk were 
about 40% for ever having had FOBT 
and 50% for endoscopic procedures, 
compared with never having under-
gone CRC screening. The reduction 
in CRC incidence was observed up 
to 4 years after baseline and applied 
most strongly to rectal cancer.
Although our data cannot be used 
to directly evaluate CRC screening 
effectiveness, they are largely consist-
ent with trial-based evidence on the 
efficacy of CRC screening in reduc-
ing CRC incidence and mortality. A 
meta-analysis of four randomised 
controlled trials (RCTs) indicated 
that those allocated to FOBT had a 
2  Adjusted hazard ratios for the associations between diff erent screening procedures and incidence of colorectal cancer in the 
45 and Up Study
Total no. 
No. of colorectal 
cancer cases
Adjusted HR 
(95% CI)
0.2 0.4 0.6 0.8 1
Hazard ratio (95% CI)
Never screened 103 977 682 1.00 (reference)
Ever screened 92 487 414 0.56 (0.49–0.63)
 3 years ago 57 540 250 0.58 (0.50–0.68)
> 3 years ago 29 424 138 0.59 (0.49–0.71)
Ever FOBT* 46 557 218 0.61 (0.52–0.72)
 3 years ago* 34 763 157 0.61 (0.51–0.73)
> 3 years ago* 10 250 51 0.62 (0.46–0.82)
Ever endoscopy† 59 504 248 0.50 (0.43–0.58)
 3 years ago† 34 993 135 0.47 (0.39–0.57)
> 3 years ago† 23 039 107 0.56 (0.45–0.68)
Primary screening by endoscopy‡ 42 511 179 0.48 (0.40–0.57)
 3 years ago‡ 21 824 84 0.47 (0.37–0.59)
> 3 years ago‡ 18 381 82 0.53 (0.42–0.67)
HR = hazard ratio. FOBT = faecal occult blood testing. Numbers for analyses on time since screening do not add up to number of cases used for overall 
analyses because individuals without information on time since last screening were excluded from these analyses. HRs were obtained from proportional 
hazards regression, and were stratified by age and adjusted for demographic and health-related variables as described in the text, in addition to footnoted 
adjustments. * Adjusted for having undergone primary endoscopy. † Adjusted for having undergone FOBT only. ‡ Adjusted for having undergone FOBT or 
FOBT and endoscopy. 
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16% reduction in CRC mortality com-
pared with those not randomised to 
screening,18 while risk reduction may 
be even greater among those who ad-
here to a screening program.19 Based 
on data from five RCTs, sigmoido-
scopy-based screening reduced CRC 
incidence by 18%.3 Colonoscopy is 
considered the “gold standard” for 
examination of the entire colon and 
rectum; however, its efficacy in rela-
tion to CRC incidence and mortality 
has never been investigated in RCTs 
and its magnitude of effect is cur-
rently unknown.20
Our observation of a 50% lower 
CRC risk after screening endoscopy 
is in line with two observational 
prospective studies from the United 
States.10,11 Interestingly, the reduc-
tion in CRC risk after endoscopy was 
greater for rectal and distal colon can-
cers than tumours located in the prox-
imal colon. In our study, we reported 
combined estimates for sigmoidosco-
py and colono scopy. Because flexible 
sigmoido scopy only allows inspec-
tion of (and polyp removal from) the 
distal but not proximal colon, our 
finding of stronger risk associations 
with distal CRC might be due to the 
lack of association of sigmoidoscopy 
with proximal colon cancer. However, 
only a small proportion of screened 
individuals reported having under-
gone sigmoidoscopy (< 6% v 64% co-
lonoscopy and 52% FOBT), with 70% 
of them additionally having had 
colonoscopy, presumably as a follow-
up of abnormal sigmoidoscopy. Our 
risk estimates are thus likely to be 
driven by the effect of colonoscopy. 
Differences in the strength of associa-
tion with colonoscopy for proximal 
and distal colon cancers have been 
noted previously.11,21,22 A recent long-
term prospective study from the US 
found reductions in incidence of 
30% and 75% for proximal and distal 
CRC after colonoscopy, respectively, 
which compares well with our find-
ing.11 Possible explanations for the 
difficulties in detecting precancer-
ous lesions in the proximal colon may 
include incomplete colonoscopies or 
poor quality of bowel preparation 
resulting in missed lesions; flat le-
sions which are difficult to detect 
and remove; and the occurrence of 
rapidly growing cancers.21,23 Large, 
long-term RCTs on the effectiveness 
and the magnitude of effect of colo-
noscopy on the incidence of CRC and 
its subtypes in the general population 
are needed and underway, but results 
are unlikely to be available within the 
next 10 years.24,25
The association of FOBT with re-
duced CRC incidence appeared to be 
driven primarily by the strong rela-
tion of FOBT with rectal cancers in 
our study. The ability of FOBT to de-
tect proximal colon cancers has been 
debated.26 FOBT exploits the tendency 
of CRC and large adenomas to bleed; 
however, haemoglobin from proximal 
neoplasia may degrade on passage 
to the anus, which may affect the ac-
curacy of the test. In a systematic re-
view of seven prospective screening 
studies, most of the studies indicated 
lower sensitivity for detecting proxi-
mal advanced neoplasia than for dis-
tal advanced neoplasia.26 In general, 
sensitivity for detecting precancerous 
lesions is low for guaiac faecal occult 
blood tests (16%–31%) and moderate 
for the newer faecal immunochemical 
tests (27%–67%).27
The lack of differences in the as-
sociation of screening with CRC in-
cidence across the two periods may 
be due to the relatively short time 
frame of our study. Case–control 
studies have suggested that the effect 
of endoscopy sustains for more than 
10 years with little attenuation.28,29 
For FOBT, the effect attenuation we 
observed after excluding cases oc-
curring during the first 2 years of fol-
low-up may reflect its ability to detect 
early-stage disease and its rather low 
to moderate sensitivity for detecting 
precancerous lesions.27
The results of our study need to be 
interpreted against the backdrop of its 
limitations. First, as has been noted, 
the results cannot be directly trans-
lated into effectiveness of population 
screening. Greater emphasis should 
be placed on the data as providing 
insights into the likely experiences 
of consumers and on health services 
use after CRC screening. Second, 
3  Adjusted hazard ratios for the associations between diff erent colorectal cancer (CRC) screening procedures to the incidence of diff erent subtypes of 
CRC in the 45 and Up Study (n = 196 464)
Proximal colon (n = 454) Distal colon (n = 240) Rectum (n = 349)
Screening variables Total no. No. Adjusted HR (95% CI) No. Adjusted HR (95% CI) No. Adjusted HR (95% CI)
Never screened (reference) 130 977 245 1.00 (reference) 149 1.00 (reference) 253 1.00 (reference)
Ever screened 92 487 209 0.76 (0.62–0.92) 91 0.60 (0.46–0.78) 96 0.35 (0.27–0.45)
 3 years ago 57 540 128 0.82 (0.66–1.03) 56 0.63 (0.46–0.87) 57 0.33 (0.25–0.45)
> 3 years ago 29 424 68 0.76 (0.58–1.00) 30 0.62 (0.42–0.92) 34 0.38 (0.27–0.54)
Ever FOBT* 56 557 106 0.87 (0.69–1.10) 53 0.72 (0.52–1.00) 52 0.36 (0.26–0.49)
 3 years ago* 34 763 76 0.83 (0.64–1.09) 36 0.69 (0.47–1.01) 39 0.36 (0.25–0.51)
> 3 years ago* 10 250 24 0.79 (0.52–1.21) 15 0.88 (0.51–1.50) 12 0.35 (0.20–0.64)
Ever endoscopy† 59 504 133 0.73 (0.58–0.90) 46 0.46 (0.33–0.65) 58 0.33 (0.25–0.45)
 3 years ago† 34 993 73 0.68 (0.52–0.89) 26 0.47 (0.30–0.72) 31 0.30 (0.20–0.43)
> 3 years ago† 23 039 56 0.74 (0.55–1.00) 20 0.52 (0.32–0.84) 26 0.38 (0.25–0.57)
Primary screening by endoscopy‡ 42 511 92 0.71 (0.55–0.90) 30 0.43 (0.29–0.64) 38 0.32 (0.23–0.45)
 3 years ago‡ 21 824 49 0.72 (0.52–0.98) 16 0.45 (0.27–0.76) 16 0.26 (0.16–0.43)
> 3 years ago‡ 18 381 42 0.70 (0.50–0.97) 14 0.45 (0.26–0.79) 21 0.39 (0.25–0.61)
HR = hazard ratio. FOBT = faecal occult blood testing. HRs were obtained from proportional hazards regression, and were stratified by age and adjusted for demographic and health-
related variables as described in the text, in addition to footnoted adjustments.* Adjusted for having undergone primary endoscopy. † Adjusted for having undergone FOBT only. 
‡ Adjusted for having undergone FOBT, or FOBT and endoscopy. 
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assignment of screening status was 
based on self-report and may be sub-
ject to misreport. A recent meta-anal-
ysis, however, indicates self-reports 
of CRC screening to be reasonably 
reliable.30 Although the question-
naire explicitly asked for screening, 
we cannot rule out that some partici-
pants may have reported having had 
endoscopy as a diagnostic test (due to 
symptoms) rather than as true screen-
ing (as part of a routine health check-
up), and our risk estimates may not 
entirely represent the effect of true 
screening. This potential mixture 
of effects, however, will most likely 
have biased our estimates towards 
the null, and the protective effect of 
true screening by endoscopy might 
be even stronger. Third, we were not 
able to take into account information 
about the number of previous screens 
and a potential diagnosis or removal 
of polyps. Removal of polyps would 
have altered individuals’ CRC risk. 
Further, people having polyps re-
moved would be more likely to par-
ticipate in screening regularly. People 
screened more than once will have 
a lower risk of CRC irrespective of 
whether screening is beneficial, as 
they must not have had CRC detected 
on a previous screen and will later be 
diagnosed only if the last screen pro-
duced a false-negative result or can-
cer developed afterwards. Similarly, 
because we excluded pre-existing 
CRC at baseline, all incident cases 
must have had either a false-negative 
screen or developed cancer since last 
screening. Fourth, we lacked infor-
mation on the type of FOBT and 
sigmoidoscopy. Finally, we had no 
information on screening during 
follow-up; however, the likelihood 
of bias due to repeated screening ap-
pears low, given the relatively short 
follow-up in our study.
In conclusion, this population-
based prospective study illustrates 
a lower CRC risk among individu-
als with a history of CRC screening, 
compared with individuals who have 
never had CRC screening, through 
either FOBT or endoscopy, lasting for 
at least 4 years after screening. 
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